Please login to the form below

telaprevir

This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.

Leiden reassures on key role at Vertex

The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.

Latest news

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
Access to new hep C treatments put under the spotlight

telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
FDA approves four new medicines across multiple areas

and Vertex' Incivek (telaprevir).
J&J starts to feel biosimilar competition bite

toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Top biotech firms saw sales jump in 2014

Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Deal Watch table for November 2013

172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
Interview: Cesar Rodriguez, Janssen

Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.